PERKINELMER INC's ticker is PKI and the CUSIP is 714046109. A total of 516 filers reported holding PERKINELMER INC in Q2 2023. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FIRST TRUST ADVISORS LP | 133,547 | $15,864,038 | 0.02% |
| Citadel Advisors | 752,358 | $89,372,607 | 0.02% |
| CANADA LIFE ASSURANCE Co | 65,010 | $7,759 | 0.02% |
| Spire Wealth Management | 4,000 | $475,160 | 0.02% |
| Rockefeller Capital Management L.P. | 38,925 | $4,623,981 | 0.02% |
| Edgestream Partners, L.P. | 1,705 | $202,537 | 0.02% |
| Sumitomo Mitsui DS Asset Management Company, Ltd | 10,115 | $1,201,561 | 0.02% |
| Vanguard Personalized Indexing Management, LLC | 4,808 | $571,108 | 0.02% |
| Quent Capital, LLC | 938 | $111,409 | 0.02% |
| MARTIN CURRIE LTD | 4,210 | $500,106 | 0.02% |
| Tidal Investments LLC | 4,735 | $562 | 0.02% |
| NOMURA ASSET MANAGEMENT CO LTD | 31,170 | $3,702,684 | 0.02% |
| Handelsbanken Fonder AB | 27,160 | $3,226 | 0.02% |
| Skandinaviska Enskilda Banken AB (publ) | 22,345 | $2,654 | 0.02% |
| Curi RMB Capital, LLC | 4,002 | $475,398 | 0.02% |
| Quadrature Capital Ltd | 5,967 | $708,760 | 0.02% |
| DEUTSCHE BANK AG\ | 261,123 | $31,018,801 | 0.02% |
| BARCLAYS PLC | 217,122 | $25,791 | 0.02% |
| Vontobel Holding Ltd. | 23,054 | $2,738,585 | 0.02% |
| Symmetry Partners, LLC | 2,337 | $278 | 0.02% |
About PERKINELMER INC
PerkinElmer Inc. is a global leader in providing innovative solutions for the life sciences and diagnostics markets. The company's products and services are used by researchers, clinicians, and laboratories around the world to improve human health and advance scientific discovery.
PerkinElmer's portfolio includes a wide range of instruments, reagents, software, and services that enable customers to detect, analyze, and interpret complex biological and chemical information. The company's offerings span the entire drug discovery and development process, from target identification and validation to clinical trials and post-market surveillance.
One of PerkinElmer's key strengths is its expertise in imaging and detection technologies. The company's instruments are used to visualize and quantify biological processes at the cellular and molecular level, providing researchers with valuable insights into disease mechanisms and potential therapeutic targets.
PerkinElmer has also made significant investments in the field of diagnostics, with a focus on developing innovative solutions for early disease detection and personalized medicine. The company's offerings in this area include genetic testing, infectious disease screening, and cancer diagnostics.
Overall, PerkinElmer is well-positioned to benefit from the growing demand for advanced technologies in the life sciences and diagnostics markets. With a strong track record of innovation and a commitment to customer service, the company is poised for continued success in the years ahead.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists PERKINELMER INC's shareholders in Q2 2023. To view PERKINELMER INC's shareholder history, click here.